Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Safety by treatment phase and age when treating FLT3-ITD-mutated AML with quizartinib and chemo

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the findings of an analysis of safety data from the QuANTUM-First trial (NCT02668653), which investigated the addition of quizartinib to chemotherapy for the treatment of patients with FLT3-ITD-mutated acute myeloid leukemia (AML). Infections and cytopenias were observed with quizartinib across all phases of treatment (induction, consolidation, and continuation), and in some phases, the rates of these adverse events were higher than in the placebo group. There were also higher rates of treatment discontinuation and dose reduction in the quizartinib arm during the continuation phase and a higher early mortality rate at days 30 and 60. Dr Erba concludes that the safety profile supports long-term use of quizartinib with chemotherapy up to 144 weeks; however, patients’ quality of life must be considered, especially in patients over the age of 75. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Forma: Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Amgen: Research Funding; Macrogenics: Consultancy, Research Funding; Syros: Consultancy; Servier: Consultancy, Honoraria, Research Funding; Kura Oncology: Consultancy, Research Funding; Trillium: Consultancy; ALX Oncology: Research Funding; Gilead: Research Funding; Jazz Pharma: Consultancy, Honoraria, Research Funding; Takeda: Consultancy; Forty-Seven: Research Funding; Ascentage: Research Funding; Pfizer: Consultancy; Incyte: Consultancy, Honoraria; Immunogen: Consultancy, Research Funding; Glycomimetics: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Sunesis Pharmaceuticals: Honoraria; Genentech: Consultancy; BMS: Consultancy, Honoraria, Other: Chair, Myeloid Neoplasms Repository Study; Celgene: Consultancy, Honoraria, Other: Chair, Myeloid Neoplasms Repository Study, Research Funding; Astellas: Consultancy; Agios: Consultancy, Honoraria, Research Funding; Daiichi Sankyo Inc.: Consultancy, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; PTE: Research Funding; Sumitomo: Research Funding.